←
Ya'el Courtney, PhD4,757 posts
Ya'el Courtney, PhD avatar

Ya'el Courtney, PhD

@ScienceYael

Jane Coffin Childs Fellow & postdoc in immunology @ Stanford Robinson lab 🦠🧬| 2024 Harvard neuro PhD @LehtinenLab • @HHMINews Gilliam ‘21 • 105/100📚 in 2026

◷ Joined June 2018▧ 607 Photos and videos
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·11 Sep 2024

🧬 With biomedical PhD applications open now, I often get asked for advice. I created a guide filled with tips from my own journey to Harvard & insights from others. I use it to lead workshops & it’s ready to help you too! ✨ Dive in and share! ⬇️ 
yaelcourtney.com/phdapplicat…

Ya'el Courtney, PhD avatar
⟳ Ya'el Courtney, PhD retweeted
Ya'el Courtney, PhD@ScienceYael·Nov 12

Personal news: in September I traveled to marry this incredibly handsome, kind, patient Australian man 🇦🇺💍. We had a perfect day supported by SO many family and friends from near and far. Kyle, thank you for supporting me in everything I do. You make it all possible. 🧵 1/3

Post attachmentPost attachmentPost attachmentPost attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 12

Shameless plug: I'm hoping to start a lab in Melbourne studying how herpesviruses contribute to autoimmunity, brain disease, and post-infectious syndromes. If you know of openings or want to talk science, my DMs are open. 3/3

Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 12

We met in Boston and always planned to end up in Australia. Kyle moved to California with me for ~3 years so I could do my dream postdoc at Stanford, far from his family and friends. I hope we're back in Aus by 2028, ideally with me as faculty 🤞 2/3

Post attachmentPost attachmentPost attachmentPost attachment
Jon Douglas avatar
⟳ Ya'el Courtney, PhD retweeted
Jon Douglas@atranscendedman·Nov 2

Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab. 8 of 12 CAR T-cell patients achieved sustained drug-free remission. biorxiv.org/content/10.64898…

Zdenek Vrozina avatar
⟳ Ya'el Courtney, PhD retweeted
Zdenek Vrozina@ZdenekVrozina·Nov 2

8 of 12 people with autoimmune disease got a single infusion of CAR-T cells and went into lasting remission - years, no drugs. With rituximab, the standard way of wiping out B cells, 0 of 15 did. A new preprint argues the gap comes down to one kind of cell - a B cell infected with EBV.🧵

Stanford researchers studied 27 autoimmune patients and found CD19 CAR T-cell therapy cleared EBV-infected, autoreactive B cells that resisted rituximab. 8 of 12 CAR T-cell patients achieved sustained drug-free remission. biorxiv.org/content/10.64898…

Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

14/ If the EBV+ autoreactive B cell decides durability, you may not need manufactured CAR T cells to clear it. A T-cell engager matched CAR T killing in vitro. It also makes repertoire reset worth testing prospectively.

Post attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

13/ 8 of 12 CAR T patients stayed in drug-free remission at a median 31 months, against 0 of 15 on rituximab. Four relapsed: one with persisting EBV+ clonotypes, one with a newly infected autoreactive clone. Both routes the model predicts.

Post attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

12/ A possible reason antibodies fail: Latency III drives NF-κB survival signaling, and EBV+ cells upregulated CD55, tied to rituximab resistance in B cell cancers. Four anti-CD20/CD19 antibodies killed EBV+ targets poorly in vitro. CAR T cells and blinatumomab did fine.

Post attachmentPost attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

11/ The cells surviving rituximab weren’t dormant. Against depth-matched EBV− cells they scored higher on MHC I, MHC II, antigen processing and activation in all 7 patients, with antigen presentation the top GSEA hit (NES 2.05, q=0.010).

Post attachmentPost attachmentPost attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

10/ And the latency distribution was similar before versus after CAR T, in cells that were newly infected. Therapy left the virus and its program in place while changing which clones carry them. What tracked with remission was the specificity of those cells.

Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

9/ EBV+ cells in healthy donors were entirely Latency 0/I. A large fraction of patient EBV+ cells ran Latency III, the program expressing EBNA2 and LMP1, which in healthy carriers appears only in freshly infected cells.

Post attachmentPost attachment
Ya'el Courtney, PhD avatar
Ya'el Courtney, PhD@ScienceYael·Nov 2

8/ We cloned 50 antibodies from individual EBV+ B cells and tested them on human cells. Before therapy: 12 of 14 autoreactive. After CAR T, in remission: 1 of 10. After rituximab: 15 of 19. EBV− repertoire, same patients: 6 of 40.

Post attachmentPost attachment